Vertex- Scottish govt. sign cystic fibrosis treatment access contract
Category: #health  By Mateen Dalal  Date: 2019-09-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Vertex- Scottish govt. sign cystic fibrosis treatment access contract

As part of the 5-year agreement, Vertex will also be collecting real world data on these medicines.

Vertex Pharmaceuticals Incorporated has reportedly announced that Scotland based patients suffering from cystic fibrosis will now be eligible to have access to ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor subsequently after signing an agreement for access.

Ludovic Fenaux, Senior VP, Vertex International, reportedly stated that the company would like to appreciate the Scottish authorities for their partnership and the flexible and collaborative way which helped both of the entities have worked together to figure out an access solution. It means that about 400 eligible patients suffering from cystic fibrosis in Scotland will now be able to have access to SYMKEVI or ORKAMBI, he further added.

Apparently, as part of the 5-year agreement, Vertex will also be collecting real world data on these medicines. This data will further support any future submissions to the Scottish Medicines Consortium (SMC).

Reportedly, Vertex cystic fibrosis medicines have been reimbursed in 17 countries around the world. These 17 countries include Australia, Austria, Denmark, Germany, Italy, the Republic of Ireland, the Netherlands, the U.S. and Sweden.

According to reliable sources, around 900 people in Scotland are suffering from CF. In the United Kingdom, 32 years is the median age of death of people suffering from CF. NHS Scotland has estimated that one in 24 Scots have a CFTR mutation. If this mutation is carried by both parents then it may lead to a baby being born with CF.

For the record, Vertex is a multinational biotechnology firm which invests in innovative initiatives to develop medicines for patients suffering from serious disorders. The company owns three approved medicines which can treat the primary cause of cystic fibrosis (CF).  Cystic fibrosis is a rare and life-threatening genetic disorder. There are several ongoing clinical and research programs going on to develop efficient treatment of CF.

Source Credit:

https://www.businesswire.com/news/home/20190912005349/en/Vertex-Announces-New-Access-Agreement-Scottish-Government

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

NHS requests urgent donations of blood plasma from COVID-19 survivors
NHS requests urgent donations of blood plasma from COVID-19 survivors
By Mateen Dalal

According to reliable sources, United Kingdom National Health Service (NHS) has filed an appeal to the individuals recuperated from novel coronavirus to donate blood plasma. The organization apparently intends to treat the people who get infected dur...

OSE Immunotherapeutics receives $228,000 to develop COVID-19 vaccine
OSE Immunotherapeutics receives $228,000 to develop COVID-19 vaccine
By Mateen Dalal

The novel coronavirus outbreak has turned out to be one of the worst disasters the world has witnessed in recent times. At times like this, pharmaceutical companies worldwide have been putting their best foot forward to find the vaccine for COVID-19....

Singapore’s ESR and Sabana REIT propose merger amid pandemic
Singapore’s ESR and Sabana REIT propose merger amid pandemic
By Mateen Dalal

Although the economic impact of the ongoing COVID-19 has significantly impacted prospects for Singapores REITs (Real Estate Investment Trusts), it seems that some resilient spots in the real estate sector will remain where they were. In the latest st...